Panacea Biotec Ltd (PANACEABIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Panacea Biotec Ltd on NSE and BSE, with an AI summary of each filing.
Please find attached details of shares dematerialised during September 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Others (Uncategorized) · 07 Oct 2026, 8:52 pm
Panacea Biotec Reports Share Dematerialization Status for Sep'26 Panacea Biotec Limited submitted its share dematerialization report under Regulation 74(5) of SEBI Regulations for Sep'26. A total of 1,000 equity shares were dematerialized during the month under NSDL, while no shares were dematerialized under CDSL. As of 30th Sep'26, the company's total dematerialized equity base reached 6,11,09,526 shares, up by 1,000 shares from 6,11,08,526 shares as of 31st Aug'26. The demat holding comprises 5,25,61,875 shares in NSDL and 85,47,651 shares in CDSL, as confirmed by Registrar and Share Transfer Agent Skyline Financial Services.
Please find attached voting results of 42nd Annual General Meeting of the Company held on 29.09.2026 along with Scrutinizer''s Report
Annual General Meeting · 02 Oct 2026, 3:12 am
Please find attached voting results of 42nd Annual General Meeting held on 29.09.2026 along with Scrutinizer''s Report
Annual General Meeting · 02 Oct 2026, 3:05 am
Please find attached proceedings of the 42nd Annual General meeting of the Company held on Tuesday, September 29, 2026 at 11:30 A.M. through Video Conferencing.
Annual General Meeting · 30 Sept 2026, 2:57 am
We would like to inform you that the Company has received 2 Demand Orders dated 28.09.2026, from the Office of the Assistant Commissioner of Income Tax, Delhi imposing penalty on account ....
Others (Uncategorized) · 29 Sept 2026, 11:27 pm
Panacea Biotec Receives ₹4.32 Crore Income Tax Penalty Demand Orders Panacea Biotec received two demand orders dated 28th Sep'26 on 29th Sep'26 from the Assistant Commissioner of Income Tax, Delhi, under Section 156 of the Income Tax Act, 1961. The orders impose an aggregate penalty demand of ~₹4.32 Crore under Section 270A for Assessment Years 2022-23 and 2023-24, alleging under-reporting/misreporting of income. The company stated the demand is not maintainable, plans to appeal before the appellate authority, and expects no material impact on its financial or operational activities.
The Company has received four Demand Orders from the Office of the Assistant Commissioner of Income Tax, Delhi under Section 156 of the Income Tax Act, 1961 ("Act") imposing penalty on ....
Others (Uncategorized) · 26 Sept 2026, 10:58 pm
Panacea Biotec Receives ₹9.82 Crore Income Tax Demand Penalty Panacea Biotec received four demand orders on 26th Sep'26 from the Assistant Commissioner of Income Tax, Delhi, under Section 156 of the Income Tax Act, 1961. The orders impose an aggregate penalty of ~₹9.82 crore under Section 270A for alleged misreporting or under-reporting of income across assessment years 2014-15 to 2016-17 and 2018-19. The company assesses the demand as non-maintainable, plans to appeal before appellate authorities, and expects no significant impact on its financials or operations.
Please note that reminder letters dated 15.09.2026, is being sent to the shareholders holding shares in physical mode, requesting them to furnish PAN and KYC details for updation, to the ....
Others (Uncategorized) · 15 Sept 2026, 8:31 pm
Panacea Biotec Issues Mandatory KYC And Demat Reminder To Physical Shareholders Panacea Biotec Ltd dispatched reminder letters dated 15th Sep'26 to physical shareholders mandating the submission of PAN, KYC, bank details, and specimen signatures to the company or its RTA, Skyline Financial Services Pvt Ltd. In accordance with SEBI circulars, failure to furnish these details restricts physical shareholders from raising grievances, lodging service requests, and receiving dividend or interest payouts, which are exclusively disbursed electronically post-compliance. Additionally, the company urged physical shareholders to register nomination details and convert their physical holdings into dematerialised form.
Please find attached intimation of letter being sent to shareholders for providing web-link for accessing Annual Report and AGM Notice for FY 2025-26
Annual General Meeting · 08 Sept 2026, 12:28 am
Please find attached Business Responsibility and Sustainability Report for FY 2025-26
Others (Uncategorized) · 08 Sept 2026, 12:17 am
Panacea Biotec Discloses FY25-26 Business Responsibility and Sustainability Report Panacea Biotec submitted its standalone BRSR for FY25-26 on 7th Sep'26. The company reported standalone turnover of ₹4,134.92m, with pharmaceuticals contributing 100% and exports accounting for ~65% across ~37 countries. Net worth stood negative at ₹(487.92)m. Operational metrics showed energy intensity improving slightly to 53.25 GJ/₹m turnover (vs 53.55 YoY) and water intensity dropping to 45.34 kl/₹m turnover (vs 56.06 YoY). Total Scope 1 and Scope 2 GHG emissions reached 23,627.64 tCO₂e. Additionally, accounts payable days shortened significantly to 158 days from 230 days in FY24-25.
Please find attached Annual Report for FY 2025-26
Others (Uncategorized) · 08 Sept 2026, 12:13 am
Please find attached Annual Report for Financial Year 2025-26 including Notice of AGM
Annual General Meeting · 08 Sept 2026, 12:00 am
Please find attached details of shares dematerialised during August 2026. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd. regarding ....
Others (Uncategorized) · 07 Sept 2026, 11:11 pm
Panacea Biotec Reports Share Dematerialization Update for Aug'26 Panacea Biotec reported the dematerialization of 3,000 equity shares during Aug'26, comprising 1,000 shares via NSDL and 2,000 shares via CDSL. As of 31st Aug'26, the company's cumulative dematerialized share count rose to 6,11,08,526 equity shares from 6,11,05,526 shares as of 31st Jul'26. The total dematerialized holding is split across 5,24,39,796 shares in NSDL and 86,68,730 shares in CDSL, as verified by registrar Skyline Financial Services under SEBI Regulation 74(5).
Please find attached Unaudited Financial Results for quarter ended June 30, 2026.
Financial Result · 14 Aug 2026, 12:22 am
Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 19,957 (+19.7% YoY | +19.7% QoQ) ■ EBITDA: 567 (Loss to Profit YoY | +120.6% QoQ) ■ EBITDA Margin (%): 2.8 (Loss to Profit YoY | +130 bps QoQ) ■ PAT: 230 (-43.2% YoY | +342.3% QoQ) ■ EPS (INR): 0.38 (-42.4% YoY | +375.0% QoQ) Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Vaccines ■ Revenue: 13,467 (+20.0% YoY | +24.8% QoQ) ■ EBIT: 747 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 5.5 (Loss to Profit YoY | Loss to Profit QoQ) Formulations ■ Revenue: 6,490 (+19.2% YoY | +10.4% QoQ) ■ EBIT: -390 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -6.0 (Profit to Loss YoY | Profit to Loss QoQ)
Please find attached Outcome of Board Meeting held on August 13, 2026.
Outcome · 14 Aug 2026, 12:16 am
Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 19,957 (+19.7% YoY | +19.7% QoQ) ■ EBITDA: 567 (Loss to Profit YoY | +120.6% QoQ) ■ EBITDA Margin (%): 2.8 (Loss to Profit YoY | +130 bps QoQ) ■ PAT: 230 (-43.2% YoY | +342.3% QoQ) ■ EPS (INR): 0.38 (-42.4% YoY | +375.0% QoQ) Panacea Biotec Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) Segmental Performance Vaccines ■ Revenue: 13,467 (+20.0% YoY | +24.8% QoQ) ■ EBIT: 747 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBIT Margin (%): 5.5 (Loss to Profit YoY | Loss to Profit QoQ) Formulations ■ Revenue: 6,490 (+19.2% YoY | +10.4% QoQ) ■ EBIT: -390 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -6.0 (Profit to Loss YoY | Profit to Loss QoQ)
Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 13 Aug 2026, 5:30 am
Panacea Biotec Board Meeting to Approve Q1FY27 Results on Aug 13, 2026 Panacea Biotec has scheduled a Board of Directors meeting on 13 Aug'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter ended 30 Jun'26. In accordance with insider trading regulations, the trading window for all designated persons and their immediate relatives will remain closed from 01 Jul'26 to 15 Aug'26. This period covers the time leading up to and 48 hours after the financial results are made public.
Please find attached details of shares dematerialised during July 2026.
Others (Uncategorized) · 05 Aug 2026, 3:57 pm
Panacea Biotec Dematerialization Status for Jul'26 Panacea Biotec reported that no shares were dematerialized during Jul'26. As of 31 Jul'26, the total number of dematerialized shares stood unchanged at 6,11,05,526. This comprises 5,26,65,454 shares with NSDL and 84,40,072 shares with CDSL. The company submitted its filing under Regulation 74(5) of SEBI Regulations, confirming the status with a certificate from its Registrar and Transfer Agent, Skyline Financial Services Pvt. Ltd.
We are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million ....
Others (Uncategorized) · 05 Aug 2026, 3:09 pm
Panacea Biotec Secures UNICEF Order for Oral Polio Vaccine Panacea Biotec has received a Letter of Award from UNICEF for the supply of its bivalent Oral Polio Vaccine (bOPV). The order is valued at approximately US$8.205 million (~Rs. 78.24 Crore) and is scheduled for execution during the Calendar Year 2028. This award is part of a previously disclosed long-term supply agreement with UNICEF that runs from 1st Apr'26 to 31st Mar'30. The contract specifies the supply of bOPV in 10 and 20 dose presentations.
The Company''s wholly owned subsidiary, Panacea Biotec Pharma Ltd. has received a Show Cause Notice (SCN) dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services ....
Others (Uncategorized) · 24 Jul 2026, 3:19 pm
Panacea Biotec Subsidiary Receives ₹4.06 Crore GST Show Cause Notice Panacea Biotec's wholly-owned subsidiary, Panacea Biotec Pharma Ltd, received a Show Cause Notice from Delhi's GST authority on 23rd Jul'26. The notice alleges a total tax liability of ₹4.06 crore, comprising ₹2.27 crore in tax, ₹1.56 crore in interest, and a ₹0.23 crore penalty. This relates to an alleged excess claim of Input Tax Credit for FY22-23. The company is preparing a response and currently foresees no adverse financial or operational impact. The matter is at the show cause notice stage.
We would like to inform you that the Company has on July 16, 2026, filed appeal before the Hon''ble High Court of Punjab and Haryana, Chandigarh, against the remaining 4th award. The ....
Others (Uncategorized) · 16 Jul 2026, 8:51 pm
Panacea Biotec Receives Interim Relief in Industrial Tribunal Dispute Panacea Biotec has filed an appeal on 16 Jul'26 against the fourth of four adverse awards from an Industrial Tribunal. These awards, applicable from 2014, order the reinstatement of certain workers with 50% back wages, full back wages for 23 transferred workmen, and a wage revision. However, the High Court has passed an interim order on three prior appeals, stating no coercive steps be taken against the company. Panacea Biotec believes the awards are challengeable and does not foresee any material adverse financial or operational impact.
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Others (Uncategorized) · 13 Jul 2026, 6:39 pm
Panacea Biotec Promoter Gifts 200,000 Shares in Inter-Se Transfer Dr. Rajesh Jain, a promoter of Panacea Biotec, gifted 200,000 equity shares to Rajesh Jain HUF, an entity within the promoter group, via an inter-se transfer on 12 Jun'26. The transaction, executed at zero consideration, resulted in Rajesh Jain HUF holding a 0.09% stake. Consequently, Dr. Jain's personal shareholding decreased from 13.57% (30,217,312 shares) to 13.48% (30,017,312 shares). The transfer falls under a SEBI SAST Regulations exemption for promoter group transactions.
Please find attached disclosure which is self explanatory
Others (Uncategorized) · 08 Jul 2026, 2:12 am
Panacea Biotec Appeals Against Industrial Tribunal Awards in High Court Panacea Biotec filed appeals on Jul 06, '26, in the Punjab and Haryana High Court against three of four adverse awards from an Industrial Tribunal. The awards, related to a dispute from 2014 onwards, mandated wage revision, reinstatement, and back wages for certain workmen. Despite the ruling, the company states it does not foresee any material adverse financial or operational impact, believing the awards are challengeable. An appeal against the fourth award is also in process.
We would like to inform that no share has been dematerialised during June 2026. A copy of the certificate obtained from the Company''s RTA viz. Skyline Financial Services Pvt. Ltd. ....
Others (Uncategorized) · 07 Jul 2026, 9:16 pm
Panacea Biotec Reports No Share Dematerialization in June 2026 Panacea Biotec reported that no shares were dematerialized during Jun'26. As of 30 Jun'26, the total number of dematerialized shares stood at 6,11,05,526, unchanged from the previous month. The holdings were split between NSDL with 5,24,78,317 shares and CDSL with 86,27,209 shares. The company submitted its dematerialization status report as per SEBI regulations, confirmed by its Registrar and Transfer Agent, Skyline Financial Services Pvt. Ltd.
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Rajesh Jain
Others (Uncategorized) · 17 Jun 2026, 8:14 pm
Panacea Biotec Promoter Group Conducts Inter-se Share Transfer On 12 Jun'26, Rajesh Jain (HUF) acquired 200,000 equity shares (0.33% of diluted capital) of Panacea Biotec from promoter Dr. Rajesh Jain via an inter-se gift transaction at nil price. This is an exempt transaction under SEBI SAST Regulations. Post-acquisition, the acquirer's holding increased from nil to 0.09% of total paid-up share capital, while the transferor's stake decreased from 13.57% to 13.48%. The transfer is within the promoter group and does not trigger an open offer.
Panacea Biotec is pleased to inform the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa (sSA) and to facilitate ....
Press Release · 08 Jun 2026, 11:53 pm
Panacea Biotec to Advance Dengue Vaccine Licensure in Africa via DENSTAR Project Panacea Biotec announced on 08 Jun'26 the launch of the DENSTAR project to advance licensure for its dengue vaccine, DengiAll®, in sub-Saharan Africa and globally. The four-year initiative is funded by the Global Health EDCTP3 JU, supported by the EU. Panacea is a key partner in the 10-member consortium, which will conduct Phase I/III studies to confirm the vaccine's safety and efficacy. DengiAll®, currently in late-stage development in India, is a single-dose vaccine targeting all four dengue serotypes without requiring prior serological testing.
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Others (Uncategorized) · 05 Jun 2026, 11:17 pm
Panacea Biotec Promoter Group to Complete Inter-Se Share Transfer Panacea Biotec promoter Dr. Rajesh Jain will transfer 2,00,000 equity shares (0.09% of share capital) to promoter group entity Rajesh Jain (HUF) via an off-market gift. The transaction is scheduled for on or after 12 Jun'26 at a nil price. This inter-se transfer is exempt from open offer requirements. Post-transaction, Dr. Rajesh Jain's holding will decrease from 13.57% to 13.48%, while Rajesh Jain (HUF)'s stake will become 0.09%. The total promoter group shareholding remains unchanged.